SCHEMBL6212435

SCHEMBL6212435

CCC(NC(=O)CC#N)NC(=O)CC#N

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MCL1 Q07820 5/20 0.54
ALDH1A1 P00352 6/20 0.39
GAA P10253 2/20 0.39
ACACB O00763 2/20 0.38
KMT2A Q03164 2/20 0.35
KDM4E B2RXH2 4/20 0.35
HSD17B10 Q99714 3/20 0.35
POLB P06746 2/20 0.35
TDP1 Q9NUW8 2/20 0.35
MAPT P10636 2/20 0.35
MEN1 O00255 1/20 0.35
USP2 O75604 1/20 0.35
HPGD P15428 1/20 0.35
CYP3A4 P08684 1/20 0.34
HTT P42858 1/20 0.34
CYP1A2 P05177 1/20 0.33
CYP2C19 P33261 1/20 0.33
CTSS P25774 1/20 0.33
CTSK P43235 1/20 0.33
CA12 O43570 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6321739 0.83 MCL1 (0.54) MCL1ALDH1A1GAAACACBKMT2A
SCHEMBL6317467 0.81 MCL1 (0.52) MCL1ALDH1A1GAAACACBKMT2A
SCHEMBL1896933 0.77
SCHEMBL10428329 0.76 MCL1 (0.47) MCL1ALDH1A1GAAACACBKMT2A
SCHEMBL8015155 0.76
SCHEMBL6317395 0.74 MCL1 (0.52) MCL1ALDH1A1GAAACACBKMT2A
SCHEMBL11523812 0.74 MCL1 (0.52) MCL1ALDH1A1GAAACACBKMT2A
SCHEMBL8075957 0.74 MCL1 (0.44) MCL1ALDH1A1GAAACACBKMT2A
SCHEMBL29232958 0.72 MCL1 (0.50) MCL1ALDH1A1ACACBKDM4EHSD17B10
SCHEMBL30628698 0.72 MCL1 (0.50) MCL1ALDH1A1ACACBKDM4EHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0748219-B8 COMPOUNDS FOR THE TREATMENT OF DISORDERS RELATED TO VASCULOGENESIS AND/OR ANGIOGENESIS SUGEN INC (US) 2005-06-08 EP disclosed
EP-0748219-B1 COMPOUNDS FOR THE TREATMENT OF DISORDERS RELATED TO VASCULOGENESIS AND/OR ANGIOGENESIS SUGEN INC (US) 2005-04-06 EP disclosed
US-5981569-A CAPABLE OF MODULATING TYROSINE KINASE SIGNAL TRANSDUCTION AND PARTICULARLY KDR/FLK-1 RECEPTOR SIGNAL TRANSDUCTION IN ORDER TO REGULATE AND/OR MODULATE VASCULOGENESIS AND ANGIOGENESIS; TREATMENT OF CANCER, DIABETES, HEMANGIOMA YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) 1999-11-09 US disclosed
EP-0748219-A4 COMPOUNDS FOR THE TREATMENT OF DISORDERS RELATED TO VASCULOGENESIS AND/OR ANGIOGENESIS SUGEN INC (US) 1999-06-16 EP disclosed
US-5849742-A Compounds for the treament of disorders related to vasculogenesis and/or angiogenesis SUGEN INC. (US) 1998-12-15 US disclosed
US-5792771-A FOR TREATING TUMORS, VASCULAR SYSTEM DISORDERS, DIABETES, DIABETIC RETINOPATHY, RHEUMATOID ARTHRITIS AND HEMANGIOMA SUGEN, INC. (US) 1998-08-11 US disclosed
US-5763441-A ADMINISTERING TO THE PATIENT SUFFERING FROM DIABETES, GLIOMA, HEMANGIOMA, KAPOSI'S SARCOMA, OVARIAN/BREAST/PANCREATIC/COLON AND PROSTATE CANCER A BENZO(G)QUINOXALINE COMPOUNDS SUGEN, INC. (US) 1998-06-09 US disclosed
US-5712395-A BENZO(G)QUINOXALINE YISSUM RESEARCH DEVELOPMENT CORP. (IL) 1998-01-27 US disclosed
EP-0748219-A1 COMPOUNDS FOR THE TREATMENT OF DISORDERS RELATED TO VASCULOGENESIS AND/OR ANGIOGENESIS Sugen, Inc. (US) 1996-12-18 EP disclosed
WO-1995021613-A1 COMPOUNDS FOR THE TREATMENT OF DISORDERS RELATED TO VASCULOGENESIS AND/OR ANGIOGENESIS SUGEN, INC. (US) 1995-08-17 WO disclosed